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Antibody mediated activation 
of natural killer cells in malaria 
exposed pregnant women
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Holger W. Unger5,6,7, Ali Salanti8,9, Alexis Shub10, Elizabeth McCarthy10, 
Katherine Kedzierska1, Martha Lappas10, Stephen J. Kent1,11, Stephen J. Rogerson2 & 
Amy W. Chung1*
Immune effector responses against Plasmodium falciparum include antibody-mediated activation of 
innate immune cells, which can induce Fc effector functions, including antibody-dependent cellular 
cytotoxicity, and the secretion of cytokines and chemokines. These effector functions are regulated 
by the composition of immunoglobulin G (IgG) Fc N-linked glycans. However, a role for antibody-
mediated natural killer (NK) cells activation or Fc N-linked glycans in pregnant women with malaria 
has not yet been established. Herein, we studied the capacity of IgG antibodies from pregnant 
women, with placental malaria or non-placental malaria, to induce NK cell activation in response to 
placental malaria-associated antigens DBL2 and DBL3. Antibody-mediated NK cell activation was 
observed in pregnant women with malaria, but no differences were associated with susceptibility to 
placental malaria. Elevated anti-inflammatory glycosylation patterns of IgG antibodies were observed 
in pregnant women with or without malaria infection, which were not seen in healthy non-pregnant 
controls. This suggests that pregnancy-associated anti-inflammatory Fc N-linked glycans may dampen 
the antibody-mediated activation of NK cells in pregnant women with malaria infection. Overall, 
although anti-inflammatory glycans and antibody-dependent NK cell activation were detected in 
pregnant women with malaria, a definitive role for these antibody features in protecting against 
placental malaria remains to be proven.
Plasmodium falciparum, the main causative agent of malaria, poses a serious threat to the health of pregnant 
women and to their unborn babies. Malaria in pregnant women can not only cause maternal death and life-
threatening symptoms, such as anemia, pulmonary edema, hypoglycemia, puerperal sepsis, but also miscar-
riages, stillbirths, prematurity and fetal growth  restriction1. Globally, malaria contributes to more than 20% 
of all maternal deaths in malaria endemic  areas1. Pregnant women are more susceptible to malaria than their 
non-pregnant  counterparts2, not only due to immunological changes during pregnancy, but also to the unique 
characteristics of P. falciparum parasites that can accumulate and sequester in the maternal blood spaces of the 
 placenta3,4. In placental malaria, a single member of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) 
 family5,6, called VAR2CSA, is expressed on P. falciparum-infected erythrocytes (IEs), and mediates adhesion 
to the glycosaminoglycan chondroitin sulphate A (CSA), on the syncytiotrophoblast cell surface lining of the 
maternal blood  spaces7–10. This adhesion avoids splenic clearance of IEs from the blood circulation, which leads 
to inflammation and localized endothelial dysfunction of the  placenta11. The variant surface antigen VAR2CSA 
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is a large ~ 350 kDa transmembrane protein consisting of a cytoplasmic acidic terminal segment, six extracellular 
Duffy binding-like (DBL) domains, four inter-domain (ID) regions, and a N-terminal  segment12,13 (Fig. 1a).
Whilst antibody (Ab) responses to several VAR2CSA domains are positively associated with the presence of 
placental and peripheral infections, there is little evidence that Ab levels to recombinant proteins protect from 
placental  malaria14. However, studies have shown that immunoglobulin G (IgG) Abs recognize VAR2CSA in a 
sex-specific and parity-dependent  manner10. High anti-VAR2CSA IgG levels can be found in multigravid preg-
nant women in P. falciparum-endemic  regions15, and women with high plasma levels of anti-VAR2CSA IgG have 
a decreased risk of delivering low-birthweight  babies10. The predominant IgG subclasses produced in response to 
P. falciparum in pregnancy are IgG1 and  IgG315–17. Both IgG subclasses have been linked to protective immunity 
against P. falciparum  infections18,19, possibly due to opsonization of IEs and the Ab-mediated activation of Fc 
gamma receptor (FcγR) expressing innate immune cells including phagocytes and natural killer (NK)  cells20,21.
NK cells can mediate Ab-dependent cellular cytotoxicity (ADCC) upon recognition of target cells via 
FcγRIIIa22, which is hypothesized to play a possible role in direct cytotoxic killing of IEs, and therefore is sug-
gested to be beneficial against P. falciparum  infections23. Ab-mediated activation of NK cells can also induce 
the secretion of a range of cytokines, including interferon gamma (IFNγ) and tumor necrosis factor alpha 
(TNFα)24–26. These cytokines may be beneficial during the early phase of Plasmodium infection by reducing 
 parasitemia22,23. However, overproduction of pro-inflammatory cytokines can also result in immunopathology 
and adverse clinical outcomes, especially in  pregnancy27–29.
Figure 1.  Schematic representation of VAR2CSA and overview of cohort groups. (a) The extracellular region 
of VAR2CSA contains a N-terminal sequence (NTS) followed by Duffy binding-like (DBL) domains and 
interdomain (ID) regions. It is anchored in the membrane by a transmembrane (TM) domain connected to 
an acidic terminal segment (ATS). (b) Plasma samples were obtained from pregnant women in Papua New 
Guinea between November 2009 and August 2012 upon enrolment into an Intermittent Preventive Treatment 
in Pregnancy (IPTp) randomized controlled trial at 14–26 gestation weeks. Samples were grouped based on 
infection status at enrolment for Fc N-linked glycan profiling and grouped based on infection status at delivery 
for functional NK cell activation assays.
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Antigen-specific Ab engagement with FcγRIIIa on NK cells was recently identified as a key vaccine-induced 
functional immune responses linked to protection by RTS,S/AS01, the only licensed P. falciparum  vaccine30. In 
addition, in vitro assays demonstrated the ability of NK cells to kill IEs via ADCC, and IgG Abs to PfEMP1 were 
sufficient to promote NK-dependent growth inhibition of P. falciparum in  IEs31. This study also showed that 
naturally acquired IgG of multigravid women specific for VAR2CSA promotes NK-dependent lysis of  IEs31. The 
ability of IgG Abs against the DBL2 and its flanking ID regions of VAR2CSA to induce ADCC is still  unexplored32, 
but is of special interest, since the two leading placental malaria vaccine candidates PRIMVAC (Institut National 
de la Santé et de la Recherche Médicale, France) and PAMVAC (University Hospital Tuebingen, Germany) both 
include DBL2  domains33,34.
Fc effector functions such as ADCC are regulated through multiple structural and genetic components of 
the Ab, FcγR, and effector  cell35, including post-translational modifications of glycans on the Fc domain of Abs, 
specifically at asparagine 297 on  IgG36. Multiple factors can influence glycosylation patterns of IgG Abs including 
age,  sex37,  epigenetics38, disease  state39,40,  infection41–43, or  vaccination44. Glycosylation patterns of IgG Abs can 
also undergo temporary changes during pregnancy, when galactosylation and sialylation of IgG Abs  increase45,46. 
This has been associated with a less inflammatory  profile47, which may contribute to acceptance of the placenta by 
the maternal immune system during  pregnancy48,49. Changes in the composition of the asparagine 297 glycan can 
also influence the binding affinity of IgG Abs to FcγRs, and thereby change the magnitude of effector functions 
initiated, including ADCC and Ab-dependent cellular  phagocytosis50. Human NK cells primarily express one Fc 
gamma receptor (FcγRIIIa), and responses through FcγRIIIa are highly regulated by IgG N-linked glycosylation, 
more so than any other human FcγR51–53. Some studies suggest that the presence/absence of key glycoforms can 
modulate FcγR affinity and ADCC activity by up to 20-fold36,51,54,55.
Here, we investigate the ability of IgG Abs of pregnant women from a malaria-endemic area specific to DBL2 
and DBL3 (both VAR2CSA domains) to activate human primary NK cells from malaria-naïve donors to secrete 
IFNγ and TNFα cytokines, and upregulate CD107a expression, which is a surrogate for granzyme B degranula-
tion and ADCC  activity56. In addition, we evaluated pregnancy-associated glycosylation patterns of IgG Abs 
and their effect on NK-mediated effector functions in the context of P. falciparum infection during pregnancy.
Results
Primary human NK cells are activated by DBL2 or DBL3-specific IgG Abs from pregnant women 
with malaria. NK cells are major innate immune mediators of cytotoxicity. To evaluate the capacity of DBL2 
and DBL3-specific IgG Abs to induce NK-mediated effector functions, we used purified IgG from two groups 
of pregnant women at mid pregnancy with peripheral P. falciparum parasitemia at delivery, and who were either 
positive (N = 50) or negative for P. falciparum IEs in the placenta (N = 27) (Fig. 1b).
We modified previously described Ab-dependent NK cell activation assays that have been utilized to assess 
responses to influenza, human immunodeficiency virus (HIV) and Mycobacterium tuberculosis  proteins24–26,57 for 
the use with VAR2CSA domain antigens (Fig. 1a). DBL2 was chosen because of its relevance in the development 
of placental malaria  vaccines33,34. DBL3 is another domain of the VAR2CSA protein, which can be recognized by 
IgG Abs generated by pregnant women with  malaria58. We characterized the ability of Abs against these domains 
to activate primary human NK cells, isolated from the blood of three malaria-naïve healthy donors. NK cells were 
identified via flow cytometry (Fig. 2a) and the levels of Ab-mediated NK cell activation in response to DBL2 and 
DBL3 were measured as indicated by intracellular cytokine production of IFNγ and TNFα, and the upregulation 
of cell surface degranulation marker CD107a (Fig. 2b-c). In order to optimize the Ab-dependent NK cell activa-
tion assay for malaria antigens, DBL2 (50–300 ng/well), DBL3 (50–300 ng/well) and IgG Ab (0.0625–0.25 mg/ml) 
concentrations were first titrated using four individual control Ab samples from pregnant women with malaria 
and a malaria-naïve individual (Fig. S1a–d).
We evaluated purified IgG from pregnant women at mid pregnancy with peripheral P. falciparum parasitemia 
at delivery, and who were either positive or negative for P. falciparum IEs in the placenta. Their purified IgG was 
assessed in the presence of DBL2 or DBL3 for induction of Ab-mediated NK cell activation (Fig. 3). For both 
antigens, we observed upregulation of NK cell degranulation (CD107a; Fig. 3a,d, DBL2: p-value = 0.0198, DBL3: 
p-value = 0.0006) mid pregnancy in pregnant women who have non-placental malaria at delivery compared to 
non-pregnant malaria-naïve healthy individuals. In addition, DBL3-specific IgG mid pregnancy from pregnant 
women with non-placental malaria at delivery induced significantly higher IFNγ and TNFα production (Fig. 3e,f, 
IFNγ: p-value = 0.0322, TNFα: p-value = 0.0184) compared to IgG from non-pregnant malaria-naïve healthy 
individuals. Relative to IgG from non-pregnant malaria-naïve healthy individuals, IgG from pregnant women 
with placental malaria were associated with significantly higher NK cell degranulation (CD107a upregulation; 
Fig. 3a, p-value = 0.0342) in response to DBL2 and TNFα production (Fig. 3f, p-value = 0.0077) in response to 
DBL3 antigen. Differences in NK cell degranulation or cytokine production between pregnant women with 
non-placental malaria and women with placental malaria were only observed in CD107a expression (Fig. 3d, 
p-value = 0.0393) in response to DBL3.
Ab-dependent NK cell activation assays were validated with the use of two control antigens. In the pres-
ence of IgG Abs from malaria-naïve healthy individuals, influenza H3 (positive control) induced NK cell 
 activation26, whereas the negative control SIV gp120 did not (Fig. S2a–c). Using human primary NK cells from 
malaria-naïve healthy donors, H3-specific Abs induced significant CD107a upregulation and cytokine expres-
sion (median expression [interquartile range (IQR)]: CD107a: 11.1% [10.2–13.1%], IFNγ: 7.0% [5.1–10.8%], 
TNFα: 6.2% [3.9–6.7%]), whereas SIV gp120 did not (median expression [IQR]: CD107a: 1.3% [0.7–1.6%], 
IFNγ: 0.3% [0.1–0.7%], TNFα: 0.0% [0.0–0.3%]). Overall, weaker NK cell degranulation or expression of intra-
cellular cytokines IFNγ and TNFα were observed in the presence of DBL2 and DBL3-specific Abs compared 
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to H3-specific Abs (Figs. 3 and S2). The mean of activation markers expressed by NK cells in the presence of 
IgG-coated DBL2 or DBL3 never reached the expression observed in the presence of influenza H3-specific IgG.
Figure 2.  Gating strategy to identify NK cell activation markers. Purified NK cells were incubated with IgG 
test samples in presence of DBL2 or DBL3 for 5 h and then analyzed via flow cytometry. Representative flow 
cytometry plots of one sample to visualize gating strategy. (a) NK cells were identified by sequentially gating on 
lymphocytes, single cells,  CD3- cells, and NK cell subsets. NK cells subsets were gated as one and assessed for 
surface CD107a expression and intracellular IFNγ and TNFα production in presence of DBL2 (b) and DBL3 (c) 
(High response = blue; malaria-naïve response = green).
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In addition, DBL2- and DBL3-binding capacities of IgG1-4 subclasses from pregnant women with placental 
(N = 50) and non-placental malaria (N = 27) were investigated via multiplex assays and correlated to the expres-
sion of CD107a, IFNγ and TNFα by Ab-activated NK cells (Figs. S3 and S4). The majority of non-placental 
malaria Ab-mediated NK cell activation was driven by IgG1; however, these correlations, if present, were weak 
to moderate (max Spearman ρ = 0.553, p-value = 0.0051). No significant correlations between IgG subclasses and 
Ab-mediated NK cell activation were observed for the placental malaria cohort, suggesting that other Ab features 
in addition to IgG subclasses may contribute to the modulation of Ab-mediated NK cell activation.
These results show that IgG to DBL2 and DBL3 from malaria-exposed pregnant women can activate NK 
cells, but that DBL2- or DBL3-specific Ab-mediated NK cell activation does not appear to predict subsequent 
placental malaria.
Polyfunctional NK cell activation profiles in pregnant women with malaria. Although levels of 
individual DBL2- or DBL3-specific NK cell activation markers did not differ the groups of pregnant women 
with and without placental malaria, it is possible that the proportion of activated NK cells expressing mul-
tiple activation markers (“polyfunctional NK cell activation”) differed between the two groups of pregnant 
women. We therefore assessed the polyfunctional ability of NK cells to secrete TNFα, IFNγ and/or to express 
CD107a in different combinations. Activated NK cells were selected based on their CD56 and CD16 expression 
 (CD56dimCD16bright and  CD56brightCD16neg/dim) (Fig. S5). The levels of CD56 expression have been associated 
with NK effector  function59.  CD56bright NK cell subsets have been combined here due to low cell numbers, but 
are mainly characterized by their poor cytotoxic capacity and their high capacity to secrete several types of post-
activation  cytokines60. The  CD56dimCD16bright NK cell population represents around 90% of peripheral blood 
NK cells and exhibit potent cytotoxic  activity60,61.
We observed only a small proportion of  CD56dim NK cells which were polyfunctional as indicated by expres-
sion of two or more activation markers (DBL2: non-placental malaria: 23.1% of  CD56dimCD16bright NK cells, 
placental malaria: 15.4%; DBL3: non-placental malaria: 16.8%, placental malaria: 12.8%). The majority of 
 CD56dimCD16bright NK cells were associated with a single function, with a great portion of NK cells exclusively 
expressing CD107a (Figs. 4 and 5). The smaller subset of  CD56brightCD16neg/dim NK cells (~ 1–5%) was more poly-
functional, more so for DBL2-specific responses than DBL3 (DBL2: non-placental malaria: 47.7% of  CD56bright 
NK cells, placental malaria: 44.6%; DBL3: non-placental malaria: 35.1%, placental malaria: 36.2%) (Figs. 4 and 5).
The polyfunctional ability of IgG Abs from pregnant women with non-placental malaria or placental malaria 
to activate NK cells was not significantly different (Figs. 4b and 5b). These findings indicate that IgG Abs against 
Figure 3.  Human NK cells lack activation in presence of DBL2- or DBL3-specific Abs from pregnant women 
with malaria. NK cells were assessed for surface CD107a expression and intracellular IFNγ and TNFα 
production in the presence of VAR2CSA subdomains DBL2 (a–c) or DBL3 (d–f). Percentage of activation 
markers expressed by NK cells (mean of three separate donors) are shown. NK cells were stimulated with 
purified IgG Abs from pregnant women mid pregnancy with placental malaria (PM; N = 50; red) or from 
pregnant women with non-placental malaria (NP; N = 27; blue) at delivery in the presence of VAR2CSA 
subdomains DBL2 or DBL3. IgG Abs from malaria-naïve donors were used as negative control (N = 8; grey). 
Activation marker expression of NK cells incubated without Abs and median of SIV gp120-specific responses 
were subtracted as background. Statistical comparison between groups was performed using a Kruskal–Wallis 
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DBL2 and DBL3 from malaria-exposed pregnant women can induce NK cells, with the main response being 
an upregulation of CD107a expression, but also with a small subset inducing polyfunctional NK cell responses.
Figure 4.  Polyfunctional responses of NK cells induced by DBL2-specific Abs from pregnant women with 
malaria. NK cells from three separate donors were stimulated with IgG from pregnant women mid pregnancy 
with non-placental malaria (N = 27), women with placental malaria (N = 50) at delivery in presence of DBL2 
and assessed for expression of CD107a, IFNγ and TNFα. (a) NK cells were selected based on their CD56 
expression  (CD56dim and  CD56bright). Pie and Bar charts show the proportion (b) and relative frequency (c) 
of each activation marker combination of only activated NK cells. (b) The pie segments correspond to NK 
cells expressing different combinations of activation markers and are color coded (pie segment legend: pink-
red) to indicate increasing polyfunctional NK cell activation. (c) The bar graph shows relative frequencies 
of combinations of activation markers by NK cells stimulated with IgG from non-placental malaria-infected 
women (blue) or women with placental malaria (red) in presence of DBL2. Mean of three NK cell donors with 
standard deviation is shown. Statistical analysis between groups was performed using multiple t tests corrected 
for multiple comparisons using the Holm-Šídák method.
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Glycan profiles of IgG Abs in pregnant women with malaria are potentially masked by preg-
nancy. Another mechanism by which the immune system regulates Ab-mediated activation of innate 
immune cells is the modulation of glycosylation patterns of IgG Abs at a single asparagine residue at position 297 
in the  CH2  domain36. N-linked glycans are composed of a core complex biantennary structure of mannose and 
Figure 5.  Polyfunctional responses of NK cells induced by DBL3-specific Abs from pregnant women with 
malaria. NK cells from three separate donors were stimulated with IgG from pregnant women mid pregnancy 
with non-placental malaria (N = 27), women with placental malaria (N = 50) at delivery in presence of 
DBL2 and assessed for expression of CD107a, IFNγ and TNFα. NK cells were selected based on their CD56 
expression  (CD56dim and  CD56bright). Pie and Bar charts show the proportion (a) and relative frequency (b) 
of each activation marker combination of only activated NK cells. (a) The pie segments correspond to NK 
cells expressing different combinations of activation markers and are color coded (pie segment legend: pink-
red) to indicate increasing polyfunctional NK cell activation. (b) The bar graph shows relative frequencies 
of combinations of activation markers by NK cells stimulated with IgG from non-placental malaria-infected 
women (blue) or women with placental malaria (red) in presence of DBL3 (bottom bar graph). Mean of three 
NK cell donors with standard deviation is shown. Statistical analysis between groups was performed using 
multiple t tests corrected for multiple comparisons using the Holm-Šídák method.
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N-acetylglucosamine (GlcNAc) with variable additions of sugars such as fucose, galactose, sialic acid and bisect-
ing GlcNAc (Fig. 6a)36. These post-translational modifications tune the affinity of IgG Abs for FcγRs, such as 
FcγRIIIa on NK cells, and regulate effector  function25,62,63. We evaluated N-linked glycosylation patterns of IgG 
Abs in pregnant women using plasma collected at 14–26 weeks’ gestation. Samples from pregnant women with 
P. falciparum infection (N = 11) and uninfected pregnant women (N = 41) at enrolment were analyzed, together 
with malaria-naïve healthy pregnant women (N = 10) and non-pregnant women controls (N = 13). N-linked 
glycosylation profiles were analyzed via microchip capillary electrophoresis-laser-induced fluorescence. No 
statistically significant differences were observed between the two groups of pregnant women (Fig. 6b–l), sug-
gesting that malaria infection in second trimester of pregnancy does not change the total IgG N-linked glycan 
profile. However, comparing N-linked glycosylation profiles of IgG from pregnant women, regardless of infec-
tion or malaria exposure status, with the profiles of uninfected non-pregnant women, the total IgG of pregnant 
women exhibited a higher degree of total galactosylation (Fig. 6b, median [IQR]: pregnant non-infected: 83.9% 
[80.9–86.3%], pregnant infected: 85.0% [75.0–87.4%], pregnant malaria-naïve healthy: 87.90% [86.1–90.6], non-
pregnant malaria-naïve healthy: 78.0% [75.2–79.3]) and total sialylation (Fig. 6c, median [IQR]: pregnant non-
infected: 19.7% [17.5–22.0%], pregnant infected: 20.8% [16.7–21.8%], pregnant malaria-naïve healthy: 20.8% 
[17.1–22.3], non-pregnant malaria-naïve healthy: 13.8% [13.3–14.7%]). No differences in total fucosylation were 
observed. Examining the distribution of specific glycan structures, significantly decreased proportions of G0 and 
G1F glycan structures were observed in pregnant women compared to non-pregnant women (Fig. 6e,h), whereas 
elevated proportions of G2 and G2S1, structures were observed in pregnant women compared to non-infected 
non-pregnant women (Fig.  6i–l). However, differences between malaria-naïve healthy pregnant women and 
malaria-exposed pregnant women were observed for G1 and G2F glycan structures (Fig. 6g,j), suggesting that 
malaria-naïve healthy pregnant women have slightly higher anti-inflammatory glycan structures (more galac-
tose and fucose) in comparison to malaria-exposed pregnant women. Placental malaria infections may induce 
slightly more inflammatory glycan structures within pregnant women. However, no significant differences were 
observed for total galactose or fucose glycan structures were compared healthy pregnant control (Fig. 6b,d).
N-linked glycosylation profiles of purified total IgG from pregnant women at 14–26 weeks of gestation were 
also assessed to determine if they could predict future clinical outcome (placental malaria status), with no sig-
nificant differences observed (Fig. S6a–k). We did note that similar differences in N-linked glycosylation profiles 
were maintained between infected pregnant and non-infected non-pregnant women. Furthermore, DBL2- and 
DBL3-specific Ab-mediated expression of activation markers by NK cells and IgG N-linked glycosylation patterns 
of malaria-exposed pregnant women did not correlate (Fig. S6), except for DBL2-mediated IFNγ production and 
total fucose (ρ = − 0.4255, p-value = 0.0108) along with a trend for DBL2-mediated CD107a expression and total 
fucose (ρ = − 0.3744, p-value = 0.0543), and DBL2-mediated TNFα production and total galactose (ρ = 0.3625, 
p-value = 0.0323). This suggests that the N-linked glycosylation profiles of total IgG in pregnant women may be 
more influenced by pregnancy than by malaria infection.
Discussion
Naturally acquired immunity to malaria is complex, and likely requires a combination of cell-mediated and 
humoral immune responses, including the secretion of cytokines, cellular cytotoxicity, and production of func-
tional Abs in order to efficiently clear  parasites18,64. It has previously been shown that antigen-specific Ab-medi-
ated phagocytosis and engagement with FcγRIIIa on NK cells are linked to protection by the sporozoite-based 
malaria vaccine RTS,S/AS0130. In addition, Ab-dependent NK cell cytotoxicity towards IEs in malaria-exposed 
individuals can inhibit P. falciparum  growth31. Furthermore, adaptive NK cells, a sub-population of differentiated 
specialized NK cells, were associated with lower parasitemia and protection against malaria infection through 
enhanced ADCC response to IEs in the presence of naturally acquired Abs from malaria-resistant  individuals32,65. 
The potential of NK cell-mediated ADCC to protect individuals against placental malaria is still to be determined. 
A limited number of studies have investigated NK cells in the placenta and in the blood at various timepoints 
during malaria  infections66–69, however none have considered the implications of ADCC. Here, we demonstrated 
that Abs generated by pregnant women with malaria from a malaria endemic area in their second trimester 
against the VAR2CSA subdomains DBL2 or DBL3 were able to induce NK cell activation, but no significant dif-
ferences in responses were associated with susceptibility to subsequent placental malaria. We observed that the 
majority of Ab-mediated NK cell activation in women with placental malaria was driven by IgG1, even though 
a recent study identified malaria-specific IgG1 and IgG3, and engagement with FcγRIIIa (linked to Ab-mediated 
NK cell activity), as key prediction parameters for protection in malaria RTS,S/AS01  vaccinees30. However, even 
though IgG3 shows high affinity to FcγRs and especially to FcγRIIIa, within this study, it did not correlate with 
NK cell activation in pregnant women. This suggests that IgG subclass distribution may not be the only factor 
that modulates NK cell activation during pregnancy, and that other IgG features, such as N-linked glycans may 
impact Ab-mediated NK cell activation. Currently, the importance of VAR2CSA-specific Ab-mediated responses 
in protection from placental malaria is unclear, as Ab responses to recombinant VAR2CSA antigens at delivery 
are associated with the presence of placental infection, and may represent markers of infection, rather than cor-
relates of  protection14. In addition, there is no malaria-specific antigen, which can be used as a universal antigenic 
control to assess blood stage parasite Ab-mediated NK cell responses.
Within our study, Ab-mediated activation of NK cells was largely associated with the upregulation of CD107a 
expression, a surrogate marker of ADCC  activity56,70, with smaller fractions of activated NK cells producing only 
IFNγ and TNFα or in combination with CD107a, suggesting that the majority of Ab-activated NK cells were 
potentially cytotoxic in the absence of inflammation. We speculate that this balance of Ab-mediated activation 
may be beneficial, as excessive secretion of pro-inflammatory cytokines, such as IFNγ and TNFα, in the placenta 
of malaria-infected women, especially in primigravidae, has been associated with placental pathology and adverse 
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Figure 6.  Glycan profiles of IgG Abs in pregnant women with malaria. (a) Schematic representation of 
N-linked glycan composition of human IgG Abs. The glycans are attached to asparagine (N) at position 297 
in the  CH2 domain of IgG and have a biantennary heptasaccharide core (solid line) and variable extensions 
(dash line), such as fucose, galactose and/or sialic acid. Relative abundance of specific types of N-linked glycan 
structures of purified IgG Abs from non-infected pregnant women (NIP; N = 41; blue), pregnant women with 
malaria infection (IP; N = 11; pink), malaria-naïve healthy pregnant women (HP; N = 10; yellow) and uninfected 
healthy non-pregnant women (H; N = 13; grey) were profiled. % of Fc glycans with the presence of (b) galactose 
(monogalactosylated or digalactosylated), (c) sialic acid and (d) fucose. (e–l) The relative prevalence of several 
major glycan structures (G0 agalactosylated, G1 monogalactosylated, G2 digalactosylated, F fucosylated, S1 
sialylated). Statistical comparison between groups was performed using a Kruskal–Wallis test corrected for 
multiple comparisons using Dunn’s multiple comparison method (p-values are shown on graphs).
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clinical  outcomes27,71. Placental malaria is associated with activation of pro-inflammatory host cells, such as 
monocytes and macrophages causing inflammation of the  placenta8,72. Our findings suggest that Ab-mediated 
activation of NK cells, potentially does not contribute to the overproduction of pro-inflammatory cytokines and 
resulting pathologies. Several studies suggest that progesterone, estrogen and cortisol dampen NK cell cytotoxic 
activities during  pregnancy73–75. However, the increased concentration of cortisol during pregnancy could also 
inhibit NK cell activity against P. falciparum  IEs76. Here, NK cells purified from whole blood of malaria-naïve 
healthy donors were used instead of pregnant women with malaria, and effects of pregnancy-associated hormones 
were not represented by non-pregnant malaria-naïve healthy donor blood NK cells.
We would like to acknowledge limitations of our study. NK cells from healthy malaria-naïve donors were 
used instead of pregnant women with malaria. This could have skewed for specific NK cell subsets, which may 
be underrepresented during pregnancy. Our work studied peripheral NK cells which may have substantially 
different responses to uterine NK cells and adaptive NK cells. Uterine NK cells are functionally different, do not 
circulate outside the uterus, and are more difficult to access for functional  studies77. The analysis of peripheral 
NK cells is however relevant in that they can access the site of infection, the syncytiotrophoblast cell surface 
lining of the maternal peripheral  blood8. Nevertheless, in future studies, parasite loads in the placenta at birth, 
or other clinical markers of disease severity, could also be considered, but this information was not collected for 
the majority of individuals in this cohort.
One limitation regarding the plate-bound Ab-mediated NK cell assay is that it does not mimic the interac-
tion between NK cell and IEs as shown  before31,78. However, our study is complementary to current placental 
malaria vaccine studies, which also only use DBL2  antigens33,34, and in vitro NK cell ADCC assays could be 
used for high-throughput screens of serum  samples32. Furthermore, additional activation markers of NK cell 
subpopulations, such as CD57, CD25, CD69 or the inhibitory receptor programmed death-1 (PD-1) could be 
considered for future  studies23,78–80.
IgG N-linked glycosylation profiles can influence the engagement of IgG Abs with FcγRIIIa on NK  cells36. 
Surprisingly, we did not observe any differences in Fc N-linked glycan profiles between pregnant women infected 
with P. falciparum and their non-infected counterparts. Consistent with previous  studies45,46, we observed a 
higher degree of galactosylation and sialylation of IgG Abs from pregnant women, regardless of malaria infection, 
compared to non-pregnant women. Overall, these results suggest that anti-inflammatory Fc N-linked glycans are 
elevated in both healthy and malaria-exposed pregnant women, which may dampen the Ab-mediated activation 
of NK cells in pregnant women with malaria infection. These changes have been associated with a less inflam-
matory profile during pregnancy. Fc N-linked glycan patterns of IgG Abs can be globally modulated during 
the course of inflammation, autoimmune disease or  pregnancy46,81. For example, in patients with lupus erythe-
matosus or rheumatoid arthritis (RA), reduced galactosylation and sialylation of IgG Abs correlates with pro-
inflammatory immune responses and disease  severity82. Intriguingly, the majority of pregnant women with RA 
undergo pregnancy-induced remission, which occurs simultaneously with the upregulation of IgG galactosylation 
and sialylation, such that inflammatory RA-associated glycosylation patterns are masked by  pregnancy83–85. We 
observe a similar increase in galactosylation and sialylation of the IgG Abs in pregnant women, regardless of 
malaria infection  status46,81. We acknowledge that the malaria-naïve healthy pregnant women in our study are 
more progressed in their pregnancy, which could affect the glycosylation profiles. However, these Fc N-linked gly-
cans may explain why secretion of pro-inflammatory cytokines was suppressed from NK cells within our assays.
In healthy pregnancy, highly galactosylated Abs may be more effectively transferred across the placenta and 
may be able to mediate CD107a degranulation of both maternal and cord NK  cells86. The transfer of maternal Abs 
across the placenta is mediated by binding to the neonatal Fc receptor (FcRn), which is a key process for neonatal 
immunity, as neonates cannot sufficiently generate IgG  Abs87. However, contradictory roles for IgG glycosylation 
on FcRn binding have been  reported86,88,89, including studies which show significant Ab galactosylation-driven 
changes in FcRn affinity and NK cell-activating Abs are selectively transferred across the  placenta86,88, while 
another study showed that placental IgG transport is not Fc glycosylation  selective89. In addition, Jennewein 
et al. considered transfer of maternal Abs across the placenta via binding to FcRn and FcγRIIIa, while other more 
recent studies suggest that FcγRIIIa do not play a role in maternal–fetal Ab  exchange87. Defining the mechanisms 
of placental transfer, including the role of Fc glycosylation, may offer novel insights for the rational development 
of maternal vaccines to enhance transfer of protective Abs to fetuses and reduce their  vulnerability86,90, and should 
be considered in the further development of vaccine candidates.
A limitation of capillary electrophoresis-laser-induced fluorescence is that not all Fc N-linked glycan profiles 
are clearly detectable. However, these additional patterns make up only a small fraction of human IgG Fc N-linked 
 glycans91, and more sensitive techniques such as liquid chromatography mass spectrometry require extensive pro-
tein clean up and in-solution digestion, in-depth proteome and glycoform  analysis92. Furthermore, the evaluation 
of DBL2- and DBL3-specific IgG glycosylation profiles would allow us to more accurately assess the contribution 
of N-linked glycans to Ab-mediated NK cell activation, unfortunately these assays require large volumes of plasma 
 samples25,93, which were not available for this cohort. Previous studies examining antigen-specific N-linked 
glycosylation of IgG from HIV-infected pregnant women have observed significantly different profiles between 
HIV, tetanus and pertussis toxin specific-IgG94, thus future studies where adequate sample is available should 
assess for malaria-specific IgG glycan patterns. Vaccine studies assessing healthy non-pregnant volunteers have 
demonstrated that antigen-specific IgG glycosylation profiles can be modulated by  vaccination44. It is still unclear 
if antigen-specific IgG glycosylation profiles can be modulated in pregnant women, or if pregnancy-associated 
global glycan changes will mask any antigen-specific glycosylation effects as observed in  RA83–85. Determining 
if antigen-specific Ab glycosylation patterns are associated with clinically relevant outcomes of placental malaria 
could inform the design of the next generation of maternal  vaccines95. Overall, our study highlights the necessity 
to better understand Ab effector functions, such as Ab-mediated NK cell activation, and the potential effect of 
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N-linked glycans modulation during pregnancy upon protection from, or susceptibility to, malaria and other 
infectious diseases.
Methods
Study participants. During a randomized controlled trial of Intermittent Preventive Treatment in Preg-
nancy (IPTp), plasma samples were collected from pregnant women in Madang Province, Papua New Guinea 
(PNG) between November 2009 and August  201296. Plasma samples were obtained upon enrolment into the pro-
spective study at 14–26 gestation weeks, when pregnant women presented at the hospital for their first medical 
examination and were stored at − 80 °C. Infection status of pregnant women was determined at collection time 
point by light microscopy of Giemsa-stained peripheral blood smears (with malaria, N = 11; without malaria, 
N = 41, 25 pregnant women had unknown malaria infection status at sample collection).
In this cross-sectional study, parasitemia status was determined at delivery by light microscopy of Giemsa-
stained peripheral blood smears, as well as by polymerase chain reaction of peripheral blood at  delivery97. Sam-
ples were categorized based on the presence of P. falciparum parasites in peripheral blood at delivery. Groups 
included women who were positive for P. falciparum IEs in the placenta (placental malaria, N = 50) or women who 
were positive for P. falciparum IEs in peripheral blood but did not show any sequestering of IEs in the placenta 
(non-placental malaria, N = 27) (Fig. 1). The groups were frequency matched for primigravidae, age, bed net 
use, rural residency and type of malaria preventive treatment received (Table 1). Ethical approval was obtained 
from the PNG Institute of Medical Research Institutional Review Board, the PNG Medical Research Advisory 
Council, and the Melbourne Health Human Research Ethics Committee.
Plasma samples from malaria-naïve healthy Melbourne donors (N = 8) were chosen as negative controls, 
because many matched women from PNG would have been exposed to malaria and skewed negative responses. 
For the Fc N-linked IgG glycan profiling, samples of malaria-naïve healthy non-pregnant women (N = 13) were 
used (age: 34.3 ± 7.7 years). Plasma samples from individual healthy Melbourne donors were obtained in accord-
ance with the University of Melbourne Human ethics approval (#1443420) and the Australian National Health 
and Medical Research Council Statement on Ethical Conduct in Human Research. Samples from malaria-naïve 
healthy pregnant women at the end of their second/beginning of their third trimester (N = 10) were obtained 
to compare pregnancy-specific Fc N-linked IgG glycan profiles (age: 31.3 ± 2.8 years; mean gestational age: 
196 ± 4 days). Ethical approval was granted by the Mercy Health Board Human Research Ethics Committee 
(R10/16). All participants provided written informed consent.
IgG antibody purification. IgG Abs were purified from plasma of pregnant women at enrolment accord-
ing to manufacturer’s protocol via Melon Gel chromatography (Melon Gel IgG Purification Kit, Thermo Fisher 
Scientific, USA)98. IgG Ab samples were centrifugated through 100  kDa Amicon Ultra filters (Merck & Co, 
USA) at 14,000 × g for 10 min to remove excess albumin proteins and buffer exchanged into phosphate buffered 
saline (PBS). The IgG concentration and purity were quantitated using a human IgG ELISA development kit 
(Mabtech AB, Sweden). The IgG Ab samples were diluted in PBS to adjust Ab concentration to 0.25 mg/ml for 
Ab-dependent NK cell activation assays and 2 mg/ml for N-linked glycan profiling. The samples were stored at 
− 20 °C until further use.
Table 1.  Characteristics of study participants. Data shown as mean [standard deviation], or number (%). IPTp 







Age (years) 24.6 [5.24] 23.7 [5.05]
Gravidity
Primigravidae 29 (58) 14 (51.9)
Secundigravidae 7 (14) 8 (29.6)
Multigravidae 14 (28) 5 (18.5)
Mean gestational age (days) 147.5 [31.3] 152.2 [19.8]
Mean maternal weight (kg) 53.5 [8.2] 54.1 [7.4]
Mean maternal height (cm) 154.6 [6.9] 148.4 [32]
IPTp regime
SPAZ 20 (40.0) 9 (33.3)
SPCQ 30 (60.0) 18 (66.7)
Residence
Urban 6 (12) 2 (7.4)
Periurban 4 (8) 7 (25.9)
Rural 38 (76) 18 (66.7)
Migrant 2 (4) 0 (0)
Bed net use 40 (80) 21 (77.8)
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Natural killer cell isolation. NK cells were isolated from heparinized whole blood from malaria-naïve 
healthy donors with RosetteSep (Stemcell Technologies, Canada) and density gradient separation via Ficoll (Bio-
Strategy Lab, Australia) centrifugation according to manufacturer’s protocols.
Antibody-dependent natural killer cell activation. Ab-dependent plate-bound NK cell activation 
assays were modified for use with DBL  antigens24–26,99. In order to compare NK cell activation induced by DBL 
domains and controls, various IgG Ab (0.0625–0.25 mg/ml) and protein (50–300 ng/well) concentrations were 
tested. Purified IgG was used to control for IgG concentration for each individual sample and to ensure no 
other components in plasma contributed to activation of NK cells. Concentrations of 200 ng of protein/well and 
0.25 mg/ml of IgG Abs were chosen to test individual samples.
High protein-binding plates (NUNC MaxiSorp flat bottom; Thermo Fisher Scientific) were coated with either 
 DBL233 or  DBL3100 (200 ng/well) at 4 °C for 12 h. Bovine serum albumin (BSA; Sigma-Aldrich, USA) was used 
to control for unspecific binding. Simian immunodeficiency virus (SIV) envelope protein gp120 (Sino Biologi-
cal Inc., China) and influenza hemagglutinin (H)3 (A/Switzerland/9715293/2013; Immune Technology Corp., 
USA) were used as negative and positive antigen controls, respectively. H3 was selected as a universal technical 
control, as all individuals have been previously exposed to influenza, and Abs to H3 are highly cross reactive 
and strong inducers of NK cell  activation24.
After washing with PBS, the plate was blocked with 1% PBS-BSA for 1 h. Purified IgG (0.25 mg/ml) was added 
to each well and incubated at 37 °C for 2 h. NK cells (0.25 × 106 cells/ml) were then incubated with anti-CD107a-
APC-H7 (BD, USA), brefeldin A (10 mg/ml; Sigma-Aldrich) and GolgiStop (BD) for 5 h at 37 °C. NK cells were 
stained for surface markers using anti-FcγRIII–BV605 (BD), anti-CD56-BUV737 (BD), anti-FcγRII-APC (Bio-
Legend, USA) and anti-CD3-PerCP (BD), and intracellularly with anti-IFNγ-PE (BD) and anti-TNFα-BV785 
(BD) via fixation with 10% paraformaldehyde and Perm B solutions (Thermo Fisher Scientific). NK cells were 
analyzed via flow cytometry and combination gates in FlowJo (BD) were used to include all NK cells expressing 
activation marker CD107a (degranulation marker), IFNγ and TNFα (cytokines). Mean fluorescence intensity 
(MFI) of NK cells incubated without Abs was subtracted as background to determine Ab-mediated activation 
and median of SIV gp120-specific responses was subtracted as non-specific NK cell activation.
Multiplex assays of antibodies binding to Duffy binding-like domains. DBL2 and DBL3 domains 
were coupled to Bio-Plex magnetic carboxylated microspheres (Bio-Rad, Hercules, USA) as per manufacturer’s 
instructions. The antigen-coupled microspheres were resuspended in storage buffer (PBS, 0.05% sodium azide), 
and stored in the dark at 4 °C for immediate use. Their concentration was determined using a hemocytometer.
The DBL-coupled microspheres were mixed, resuspended in 1% PBS-BSA and added to wells of a 96-well 
round bottom plate (Greiner Bio-One, Kremsmünster, Austria) containing plasma in a 1:100 dilution in PBS. 
The sealed plates were incubated on a plate shaker overnight at 4 °C. After incubation, the plates were centrifuged 
and washed with PBS-0.1% Tween using a magnetic plate-washer (Bio-Plex Pro wash station, Bio-Rad). The anti-
human Ab (total IgG, IgG1, IgG2, IgG3, IgG4) detectors conjugated with phycoerythrin (PE; all SouthernBiotech, 
Birmingham, USA) were added and the mixture was incubated for 2 h on a plate shaker. After washing with PBS 
and resuspending in xMAP drive fluid (Life Technologies, Carlsbad, USA), the plates were read on a Bio-Plex 
MAGPIX multiplex reader (Bio-Rad), and analysed using Bio-Plex Manager software (Bio-Rad). The median 
fluorescence intensity is directly proportional to the amount of Ab bound to the  antigens101.
IgG N-linked glycan profiling. N-linked glycan profiles of purified IgG Abs (2 mg/ml) were measured on 
the LabChip GXII Touch instrument (PerkinElmer, USA) according to the ProfilerPro glycan profiling LabChip 
GXII Touch protocol. Microchip capillary electrophoresis-laser-induced fluorescence analysis of digested and 
labelled N-linked glycans was performed. The relative prevalences of several glycan profiles of IgG Abs were 
analyzed using the LabChip GX Reviewer (PerkinElmer) software. Peaks were assigned based on migration of 
known standards and glycan  digests91. Peak area and therefore the relative prevalence of each glycan pattern was 
calculated.
Statistical methods. Statistical analyses were performed in Prism version 8 (GraphPad, USA). Statistical 
comparison of NK cell activation markers between groups was performed using Kruskal–Wallis test with Dunn’s 
multiple comparison method. Statistical comparison between groups for the analysis of activated NK cells poly-
functionality was performed using multiple t tests corrected for multiple comparisons using the Holm-Šídák 
method. Spearman’s rank correlation coefficients of antigen binding and NK cell activation were calculated. 
Kruskal–Wallis tests with Dunn’s multiple comparison method were conducted to determine the significance 
of differences observed in glycan prevalence between pregnant women and their non-pregnant counterparts. 
Statistical significance was considered when p-values were less than 0.05.
Data availability
Derived data supporting the findings of this study are available from the corresponding author upon request.
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